This article was originally posted on Pharma Boardroom May 31, 2023 | Justin Wu, 2023 Spring Intern, Bridge Consulting Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic […]
The global convergence on Africa’s vaccine manufacturing agenda
This article contains some updated information as of February 24, 2023, since the publication of our previous article “Vaccination trends among China’s elderly from COVID-19 to flu: How to avoid a catastrophe.” This article was originally posted on Pharma Boardroom.
Elder receiving a COVID-19 vaccine shot in Shanghai, May 2022 | Source: Caixin January 5, 2023 | Stefania Jiang, Associate, Bridge Consulting As the COVID-19 outbreak escalates across China, one of the best solutions to protecting vulnerable populations from severe or fatal illness has been a renewed focus on vaccination campaigns. In early December 2022, as […]
mRNA prototype from CNBG at a Scientific and Technological Innovation Exhibition in China | Source: New York Times September 14, 2022 | Nandika Nair, 2022 Summer Intern, Bridge Consulting In this article, we touch upon: The advancement in China’s vaccine R&D over time and after the COVID-19 outbreak The development of Chinese vaccines based on more […]